Progyny, Inc.

Progyny, Inc. (PGNY) Market Cap

Progyny, Inc. has a market capitalization of .

No quote data available.

CEO: David J. Schlanger

Sector: Healthcare

Industry: Medical - Healthcare Information Services

IPO Date: 2019-10-25

Website: https://www.progyny.com

Progyny, Inc. (PGNY) - Company Information

Market Cap: -|Sector: Healthcare

Company Profile

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Analyst Sentiment

83%
Strong Buy

From 11 Active Polls

1Y Forecast: $30.33

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$27

Median

$30

High Bound

$35

Average

$30

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$30.33
▲ +17.29% Upside
Low Target
$27.00
4% Risk
Median Target
$30.00
16% Mid
High Target
$35.00
35% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 PROGYNY INC (PGNY) — Investment Overview

🧩 Business Model Overview

PROGYNY operates as a fertility benefits management platform that administers employer-sponsored coverage for infertility treatment. The value chain centers on (1) enrolling covered employees under fertility benefit plans, (2) coordinating care through a curated provider network, (3) applying utilization management and clinical guidance to steer patients toward appropriate treatment pathways, and (4) managing claims and outcomes across the full care episode (from diagnosis through advanced reproductive services where covered).

The business model creates stickiness because the “service product” is not limited to matchmaking; it is the operational layer that manages administrative complexity (eligibility, referral pathways, authorizations, and benefit rules) while also embedding a consistent, data-informed approach to care navigation across repeated patient episodes and ongoing employer relationships.

💰 Revenue Streams & Monetisation Model

Revenue is primarily derived from employer and payer fertility benefit programs, structured through recurring administrative/management fees tied to covered lives and/or program administration. Incremental revenue can also arise from transaction-like components associated with the processing and management of treatment pathways under plan rules.

Margin drivers typically include: (1) utilization management effectiveness (driving appropriate treatment selection and reducing unnecessary spend), (2) the ability to administer benefits efficiently across a growing member base, and (3) the commercial terms of provider network contracting (balancing access and cost containment). The operating leverage profile improves when member volumes scale without proportional increases in centralized administration.

🧠 Competitive Advantages & Market Positioning

Primary moat: switching costs and data/operational know-how (soft switching costs with durable commercial impact). PROGYNY’s platform institutionalizes benefit administration workflows and clinical navigation through established employer contracts, curated provider networks, and recurring operational routines. Once an employer integrates PROGYNY’s fertility benefit program, replacing the program typically requires re-onboarding processes, re-contracting with provider networks, and re-establishing clinical workflow standards—creating meaningful friction for decision-makers.

Secondary moat: network depth and care-pathway execution. The company’s provider network and standardized care navigation reduce variability in patient experience and support consistent application of medical-coverage rules. This tends to make program performance (measured in utilization patterns and member journey efficiency) harder for competitors to replicate quickly.

- Competitive benchmarking: Key alternatives include WINFertility (fertility benefits administration), Maven Clinic (largely telehealth and care coordination with a different service construct), and Carrot Fertility (benefits and support services with a more consumer-oriented approach).

PROGYNY’s focus is closer to end-to-end fertility benefits administration with structured care navigation and utilization management under employer-sponsored plans. By contrast, some competitors lean more toward direct care coordination models, provider-centric services, or broader digital health engagement, which can create different economics and higher dependence on variable provider execution and member self-navigation.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is supported by several structural trends:

  • Employer-sponsored fertility coverage expansion: Companies increasingly treat fertility benefits as part of broader health and talent retention strategies, increasing the addressable base of insured lives needing specialized infertility benefits management.
  • Rising utilization and treatment complexity: Infertility management often involves multiple care steps and advanced procedures. Program administrators that can manage pathways and costs across episodes face a structural demand advantage.
  • Operational outsourcing of specialized benefits: Employers prefer delegating high-administrative-complexity programs to specialized partners with systems and provider contracting capabilities.
  • TAM expansion through plan design evolution: As benefit designs evolve (coverage rules, pre-authorization workflows, and network requirements), specialized administrators can embed themselves deeper into employer plan operations.

⚠ Risk Factors to Monitor

  • Clinical and utilization variability: Changes in patient mix, treatment intensity, or clinical outcomes can impact utilization patterns and profitability.
  • Regulatory and compliance changes: Alterations in healthcare privacy requirements, insurance/benefits regulations, or coverage mandates can increase compliance costs or constrain program design.
  • Provider network capacity and contracting risk: If partner clinics face capacity constraints or pricing pressure, access and cost management may deteriorate.
  • Technology and data security: The platform relies on sensitive health information and operational systems; cybersecurity incidents can materially damage trust and increase costs.
  • Competitive pricing pressure: Fertility benefits is an active category for providers and digital health players. Sustained margin discipline depends on maintaining differentiation in workflow execution and cost containment.

📊 Valuation & Market View

The market typically values specialized healthcare administration and technology-enabled services using a blend of EV/Revenue and EV/EBITDA frameworks, with an emphasis on growth durability and operating leverage. Key valuation drivers include sustained member and contract retention, evidence of utilization management effectiveness, improving gross margin structure, and scalable administrative overhead.

Important “needle movers” for this business model generally involve: (1) quality of employer retention and renewals, (2) growth in covered lives and program penetration, (3) stability of provider network contracting economics, and (4) demonstration that program performance supports cost containment without harming patient access and outcomes.

🔍 Investment Takeaway

PROGYNY’s long-term value proposition is anchored in specialized fertility benefits administration—an ecosystem that combines care navigation, provider network execution, and utilization management under employer-sponsored plans. The durable friction of switching programs, together with operational know-how embedded in workflows and networks, supports a defensible position versus both benefit administrators and broader digital health competitors. The investment case hinges on maintaining margin discipline while scaling employer adoption and sustaining strong program performance across evolving fertility treatment patterns.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"PGNY delivered Q1’26 revenue of $328.5M and net income of $24.2M (EPS: $0.30). Versus Q1’25, revenue rose +1.4% YoY and net income increased +60.9% YoY, with the net margin improving from 4.65% to 7.38%. QoQ, revenue slipped -2.9% from $318.4M in Q4’25, while net income jumped from $12.5M to $24.2M (+93.9% QoQ), indicating meaningful cost/other-line improvement. Profitability strengthened over the last four quarters: gross margin improved to 25.3% (Q1’26) from 24.2% (Q4’25), and operating margin expanded sharply to 10.8% from 4.8% in Q4’25 (though it remains variable quarter-to-quarter). Operating cash flow was $46.0M, and free cash flow was $39.6M in Q1’26, supporting ongoing capital returns—most notably $118.6M of share repurchases. Balance-sheet resilience remains strong: net debt is negative (net cash) at about -$108M, with total assets at $698.3M and equity at ~$439M. Total shareholder return is pressured by price: the stock is down -15.3% over the past year, with no dividend. Buybacks likely help, but market momentum remains negative; analyst targets show moderate upside (consensus $30.8 vs $18.12)."

Revenue Growth

Neutral

Revenue was $328.5M in Q1’26, up +1.4% YoY but down -2.9% QoQ vs Q4’25—modest growth with some recent softness.

Profitability

Good

Net income rose +60.9% YoY and +93.9% QoQ. Net margin expanded to 7.4% from 3.9% in Q4’25 and 4.7% in Q1’25, indicating improving earnings power.

Cash Flow Quality

Positive

Q1’26 operating cash flow was $46.0M and free cash flow $39.6M. Repurchases were significant ($118.6M) and dividends were zero, so capital return relies on cash generation.

Leverage & Balance Sheet

Positive

Strong balance sheet for a non-bank: net debt remains negative (net cash ~-$108M). Equity is high (~$439M) though total assets declined QoQ (from $742M).

Shareholder Returns

Caution

Market performance is negative (-15.3% 1y) and no dividend is paid. Buybacks likely supported returns, but total value creation is not reflected in price momentum.

Analyst Sentiment & Valuation

Positive

Consensus target ($30.8) is materially above the current price ($18.12), implying meaningful upside. Valuation multiples appear elevated, but the earnings rebound in Q1’26 improves the near-term narrative.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Progyny started 2026 with record Q1 results: revenue at the high end of expectations, with net income, EPS, and adjusted EBITDA above guidance ranges. Revenue growth was +1.4% reported, but >12% excluding the $48.5M transition-of-care contribution from a large former client that ended June 30, 2025. Management emphasized sustained, high-end member engagement and margin strength from care-management/service-delivery efficiencies plus lower stock-compensation drag. Cash generation was strong (about $446M operating cash flow; >$200M TTM for five straight quarters) and DSO improved 11 vs the prior-year Q1. The market setup also improved: early selling/renewal de-risking with favorable notifications from large clients, and pipeline inflows from Cigna plus initial traction in Progyny Select via aggregators/distributors. Q2 and full-year guidance ranges were raised, with utilization assumptions held and profitability supported by recurring efficiencies, while key risk is potential treatment/activity variability and administrative adjustment noise that management is actively mitigating via full eligibility files.

AI IconGrowth Catalysts

  • Member engagement pacing at the high end of historical range; utilization trending high-end
  • Gross margin expansion driven by efficiencies in care management/service delivery and the anticipated reduction in stock compensation expense
  • Strong early selling/renewal activity supported by de-risked renewals and favorable notifications from largest clients
  • Progress with Progyny Select via aggregators and distribution partners (incremental pipeline timing later in 2026)

Business Development

  • Cigna: first full season as a partner; traction/inflow of opportunities from the channel
  • Progyny Select: signing up aggregators and distributors; reaction described as positive (pull-through expected end of year / small-employer buying window)
  • Large unnamed client: commissioned third-party claims-data warehouse study using Progyny claims vs pre-Progyny for an 8-year period

AI IconFinancial Highlights

  • Q1 results: record first-quarter revenue at higher end of expectations; net income, EPS, and adjusted EBITDA above guidance ranges
  • Q1 revenue growth: +1.4% reported; >12% excluding $48.5 million transition-of-care revenue from the large former client (transition ended June 30, 2025)
  • Margin/cash: gross margin expanded; adjusted EBITDA margin remains healthy despite higher investment
  • Operating cash flow: approx. $446 million in Q1; >$200 million trailing twelve-month and maintained for five consecutive quarters
  • DSO: improved by 11 lower vs first quarter of prior year (sequentially built in Q1 due to payment-flow establishment with Jan 1 new client launches)

AI IconCapital Funding

  • Share repurchase: completed $200 million program
  • During quarter: repurchased >5.5 million shares for approx. $116 million (repurchase program began November; total completed at ~8.8 million shares in aggregate)
  • Liquidity/debt: $266 million total working capital as of March 31; $225 million cash/cash equivalents/marketable securities; no debt; $200 million revolver with no borrowings and no planned use

AI IconStrategy & Ops

  • Platform investments: expand capabilities of the platform; enhance member experience; extend position in women’s health/family building
  • Eligibility-file process change: moving from numeric headcount updates to receiving full eligibility files more regularly
  • Investments/incentives and margin outlook: management described investments as already contemplated and phased through 2026

AI IconMarket Outlook

  • Q2 2026 revenue guidance: $1.365B to $1.405B (+2.7% to +6.6%); excluding $17.2M transition client revenue from year-ago quarter implies +8.3% to +12.4%
  • Q2 2026 profitability guidance: adjusted EBITDA $342M to $355M; net income $25.8M to $28.7M; EPS (diluted) $0.31 to $0.35; adjusted EPS $0.50 to $0.53 (83M fully diluted shares)
  • Full-year 2026 profitability guidance (raised): adjusted EBITDA $232M to $244M; net income $103.7M to $112.3M
  • Full-year 2026 EPS guidance: $1.23 to $1.34 (diluted) and adjusted EPS $1.98 to $2.09 (approx. 84M fully diluted shares)
  • Full-year utilization assumption: 1.04% to 1.05%; ART cycle consumption per female unique: 0.93 (low) to 0.95 (high)
  • Board timing: potential decision on a new share repurchase program anticipated around May (announcement expected at that time)

AI IconRisks & Headwinds

  • Potential for variability in activity/treatments to recur (guidance assumptions at the low end reflect this possibility)
  • Revenue comparability risk from transition-of-care ending June 30, 2025 (management repeatedly adjusted comparisons to normalize impact)
  • Headline risk concerns about engagement/demand attributed to AI narrative; management stated no signs of negative impact, framing risk as mispricing vs actual dynamics
  • Client administrative true-up risk: management described as largely offset and mitigated by increasing eligibility-file receipt frequency

Q&A: Analyst Interest

  • Topic: Early commitments mix and what’s driving additional RFP activity from competitor clients: Management stated early commitments have a higher proportion from not-nows, but overall activity/commitments are positive vs last year. For competitor-client RFPs, management said there were no constructive, specific themes to share beyond observing stronger activity versus prior periods.
  • Topic: Drivers behind revenue per ART cycle and whether it persists: Management attributed a slightly higher start-of-year revenue per ART cycle to a higher proportion of new clients in consultation phases (revenue exists, but ART cycles are not yet counted). They said seasonality and how the metric evolves over the year is the more instructive comparison.
  • Topic: Eligibility-file process changes to prevent membership-count surprises: Management confirmed regular updates continue, but they are increasing the level of eligibility files from clients instead of relying on numeric headcount updates. They expect full eligibility files from most clients by year-end, improving identification/mitigation of adjustments.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the PGNY Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — Progyny, Inc. (PGNY) Financial Profile